Non-WS Questions

1. In relation to this (See highlighted part) link removed

   1. Is it correct that there was no way they could justify collecting excess blood?

   2. For how long had this been the case?

   3. Does he agree with the characterisation of lack of coordination?

2. In relation to Para 22 of this document link removed

   1. Can he address what is said here?

   2. Why would there need to be careful handling for example?

WS Questions

1. P44 - P49 - What impact(s) did he observe the ceasing of production of cryo to have?

   1. What consultation was there with him or others leading up to this move?

   2. Can he help with the rationale behind the decision?

2. P53 - Had you/they in effect accepted failure/defeat?

3. P87 - On what basis does he say that surrogate testing was “not really helpful”?

4. P94 - Should that balance of risk be made on an individual basis before each transfusion?

   1. Would, in his mind, that same logic apply to the administration of blood products such as FVIII?

   2. Should that balance of risk judgement involve the input of the patient in his view?

5. P112 - Can he explain what the “commercial challenges” were?

6. P112 - Can he explain what the “commercial reasons” were?

7. P117b - Even if there were false positives, is this not better than continuing to allow all donations to go completely untested and allowing infected donations to enter the blood supply? Or simply, some testing is better than no testing in terms of product safety?

8. P121 - Can he explain what he means by “legal questions of unfairness”?

9. P138c - Why was it best to use the ORTHO test despite the false positives?